BN Business News
Add your company to Business Communicator →

Business · 08/06/2012Updated: 10/17/2026 · 1 min read

Pfizer Withdraws FDA Approval for CELEBREX Indication for Familial Adenomatous Polyposis

Summary

Pfizer, Inc. has voluntarily withdrawn its FDA approval for the familial adenomatous polyposis (FAP) indication of CELEBREX (celecoxib) Capsules, allowing the company to waive a hearing process.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →